ICUCW

SeaStar Medical Holding Corporation

Price Chart

Latest Quote

$0.02

-0.00 (-7.85%)

Current Price

Previous Close	$0.02
Open	$0.04
Day High	$0.02
Day Low	$0.01
Volume	16,492

Fetched: 2026-06-25T09:34:09

Stock Information

Total Debt	$331K
Cash Equivalents	$9.35M
Revenue	$1.44M
Net Income	$-11.90M
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Sales	$1.44M
Income	$-11.90M
Book/sh	$1.83
Employees	17

Financial Ratios

Quick Ratio	2.41
Current Ratio	2.73
Debt/Eq	4.53

Returns & Margins

ROA	-79.24%
ROE	-302.00%
Gross Margin	93.11%
Operating Margin	-727.88%

Ownership

Insider & Institutional transactions data not available

Valuation Ratios

P/B

0.01

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$nan
SMA50	$nan
RSI	nan
ATR	nan

Shares Float	3.96M
Volatility	-1.03
Rel Volume	20.00

Performance History

Week	nan%
Month	nan%
Quarter	nan%
YTD	nan%
10 Years	nan%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$nan	16,492
2026-06-18	$0.03	0
2026-06-17	$0.03	0
2026-06-16	$0.03	0
2026-06-15	$0.03	0
2026-06-12	$0.03	0
2026-06-11	$0.03	0
2026-06-10	$0.03	0
2026-06-09	$0.03	0
2026-06-08	$0.03	0
2026-06-05	$0.03	0
2026-06-04	$0.03	0
2026-06-03	$0.03	0
2026-06-02	$0.03	0
2026-06-01	$0.03	0
2026-05-29	$0.03	0
2026-05-28	$0.03	0
2026-05-27	$0.03	0
2026-05-26	$0.03	0

About SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

📰 Latest News

SeaStar Medical Holding Corporation Q2 2026 Earnings Call Summary

Moby • 2026-05-14T12:30:00Z

SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com • 2026-05-14T05:01:51Z

SeaStar Medical (ICU) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-13T21:48:05Z

Full Transcript: SeaStar Medical Holding Q1 2026 Earnings Call

Benzinga • 2026-05-13T21:20:42Z

SeaStar Medical Holding Corp (ICU) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com • 2026-03-26T03:01:50Z

SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Highlights: Revenue Surge and ...

GuruFocus.com • 2025-11-14T05:04:37Z

SeaStar Medical (ICU) Q3 2025 Earnings Transcript

Motley Fool • 2025-11-13T22:45:28Z

SeaStar Medical Holding Corp (ICU) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com • 2025-08-14T07:14:09Z

Top Midday Gainers

MT Newswires • 2025-06-25T18:23:35Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$53,000	$0	$0	-
Cost Of Revenue	$53,000	$0	$0	-
Total Revenue	$1,234,000	$135,000	$0	$0
Operating Revenue	$1,234,000	$135,000	$0	$0
Expenses
Interest Expense	$31,000	$244,000	$1,081,000	$630,000
Total Expenses	$13,409,000	$17,977,000	$14,210,000	$11,609,000
Other Income Expense	$32,000	$-6,842,000	$-10,941,000	$50,000
Net Non Operating Interest Income Expense	$-4,000	$-143,000	$-1,081,000	$-630,000
Total Other Finance Cost	$298,000	-	-	-
Interest Expense Non Operating	$31,000	$244,000	$1,081,000	$630,000
Operating Expense	$13,356,000	$17,977,000	$14,210,000	$11,609,000
General And Administrative Expense	$5,838,000	$8,872,000	$8,237,000	$6,916,000
Other Non Operating Income Expenses	-	$-6,145,000	$-5,229,000	-
Other Operating Expenses	-	-	-	$2,190,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Net Interest Income	$-4,000	$-143,000	$-1,081,000	$-630,000
Interest Income	$325,000	$101,000	$0	-
Normalized Income	$-12,175,280	$-24,133,000	$-20,520,000	$-12,240,000
Net Income From Continuing And Discontinued Operation	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Total Operating Income As Reported	$-12,175,000	$-17,842,000	$-14,210,000	$-11,609,000
Net Income Common Stockholders	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Net Income	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Net Income Including Noncontrolling Interests	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Net Income Continuous Operations	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Pretax Income	$-12,147,000	$-24,827,000	$-26,232,000	$-12,189,000
Interest Income Non Operating	$325,000	$101,000	$0	-
Operating Income	$-12,175,000	$-17,842,000	$-14,210,000	$-11,609,000
Gross Profit	$1,181,000	$135,000	$0	-
Special Income Charges	-	$0	$-4,949,000	$0
Other
Tax Effect Of Unusual Items	$6,720	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-12,148,000	$-23,886,000	$-19,439,000	$-11,609,000
Total Unusual Items	$32,000	$-697,000	$-5,712,000	$50,000
Total Unusual Items Excluding Goodwill	$32,000	$-697,000	$-5,712,000	$50,000
EBITDA (Bullshit earnings)	$-12,116,000	$-24,583,000	$-25,151,000	$-11,559,000
EBIT	$-12,116,000	$-24,583,000	$-25,151,000	$-11,559,000
Diluted NI Availto Com Stockholders	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Tax Provision	$3,000	$3,000	$0	$1,000
Gain On Sale Of Security	$32,000	$-697,000	$-763,000	$50,000
Research And Development	$7,518,000	$9,105,000	$5,973,000	$2,503,000
Selling General And Administration	$5,838,000	$8,872,000	$8,237,000	$6,916,000
Other Gand A	$5,838,000	$8,872,000	$8,237,000	$6,916,000
Other Special Charges	-	-	$4,949,000	-
Gain On Sale Of Ppe	-	-	-	-

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$10,416,000	$-2,183,000	$-13,870,000	$-20,762,000
Total Assets	$14,158,000	$4,658,000	$3,513,000	$3,038,000
Total Non Current Assets	$578,000	$892,000	$1,205,000	$1,519,000
Other Non Current Assets	$578,000	$892,000	$1,205,000	$1,519,000
Current Assets	$13,580,000	$3,766,000	$2,308,000	$1,519,000
Prepaid Assets	$1,297,000	$1,835,000	$2,132,000	$1,460,000
Inventory	$66,000	$0	-	-
Receivables	$237,000	$112,000	$0	$12,000
Accounts Receivable	$237,000	$112,000	$0	-
Allowance For Doubtful Accounts Receivable	$-3,000	$0	-	-
Gross Accounts Receivable	$240,000	$112,000	-	-
Cash Cash Equivalents And Short Term Investments	$11,980,000	$1,819,000	$176,000	$47,000
Cash And Cash Equivalents	$11,980,000	$1,819,000	$176,000	$47,000
Cash Financial	$11,980,000	$1,819,000	$176,000	$47,000
Financial Assets	-	-	-	$1,729,000
Other Receivables	-	-	-	$12,000
Debt
Total Debt	$525,000	$574,000	$9,081,000	$8,830,000
Current Debt And Capital Lease Obligation	$525,000	$574,000	$4,744,000	$1,178,000
Current Debt	$525,000	$574,000	$4,744,000	$1,178,000
Other Current Borrowings	$525,000	$574,000	$4,744,000	$1,178,000
Net Debt	-	-	$8,905,000	$8,783,000
Long Term Debt And Capital Lease Obligation	-	-	$4,337,000	$7,652,000
Long Term Debt	-	-	$4,337,000	$7,652,000
Liabilities
Total Liabilities Net Minority Interest	$3,742,000	$6,841,000	$17,383,000	$23,800,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$4,337,000	$7,652,000
Current Liabilities	$3,742,000	$6,841,000	$13,046,000	$16,148,000
Other Current Liabilities	$1,000	$33,000	$2,307,000	$10,798,000
Payables And Accrued Expenses	$3,216,000	$6,234,000	$5,895,000	$4,172,000
Payables	$948,000	$3,046,000	$4,372,000	$1,927,000
Accounts Payable	$948,000	$3,046,000	$4,372,000	$1,927,000
Current Deferred Liabilities	-	$0	$100,000	-
Interest Payable	-	-	$19,000	$112,000
Derivative Product Liabilities	-	-	-	$0
Current Notes Payable	-	-	-	$1,178,000
Equity
Common Stock Equity	$10,416,000	$-2,183,000	$-13,870,000	$-20,762,000
Total Equity Gross Minority Interest	$10,416,000	$-2,183,000	$-13,870,000	$-20,762,000
Stockholders Equity	$10,416,000	$-2,183,000	$-13,870,000	$-20,762,000
Retained Earnings	$-151,714,000	$-139,564,000	$-114,734,000	$-88,502,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$3,844,613	$597,724	$190,461	$50,798
Share Issued	$3,844,613	$597,724	$190,461	$50,798
Tangible Book Value	$10,416,000	$-2,183,000	$-13,870,000	$-20,762,000
Invested Capital	$10,941,000	$-1,609,000	$-4,789,000	$-11,932,000
Working Capital	$9,838,000	$-3,075,000	$-10,738,000	$-14,629,000
Total Capitalization	$10,416,000	$-2,183,000	$-9,533,000	$-13,110,000
Additional Paid In Capital	$162,126,000	$137,379,000	$100,863,000	$67,739,000
Capital Stock	$4,000	$2,000	$1,000	$1,000
Common Stock	$4,000	$2,000	$1,000	$1,000
Preferred Stock	$0	$0	$0	$0
Current Accrued Expenses	$2,268,000	$3,188,000	$1,523,000	$2,245,000
Current Deferred Revenue	-	$0	$100,000	-

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-13,599,000	$-16,007,000	$-10,285,000	$-7,794,000
Operating Activities
Operating Cash Flow	$-13,599,000	$-16,007,000	$-10,285,000	$-7,794,000
Cash Flow From Continuing Operating Activities	$-13,599,000	$-16,007,000	$-10,285,000	$-7,794,000
Operating Gains Losses	$-32,000	$697,000	$5,712,000	$-50,000
Financing Activities
Issuance Of Capital Stock	$16,126,000	$17,441,000	$6,612,000	$10,001,000
Financing Cash Flow	$23,760,000	$17,650,000	$10,414,000	$7,331,000
Cash Flow From Continuing Financing Activities	$23,760,000	$17,650,000	$10,414,000	$7,331,000
Net Common Stock Issuance	$16,126,000	$17,441,000	$6,612,000	$10,001,000
Common Stock Issuance	$16,126,000	$17,441,000	$6,612,000	$10,001,000
Net Other Financing Charges	-	-	$-500,000	$-1,211,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$-834,000	$-6,102,000	$-5,270,000	$-78,000
Issuance Of Debt	$767,000	$1,692,000	$8,800,000	$3,559,000
Interest Paid Supplemental Data	$0	$553,000	$1,126,000	$6,000
Income Tax Paid Supplemental Data	$3,000	$3,000	$0	$1,000
End Cash Position	$11,980,000	$1,819,000	$176,000	$47,000
Beginning Cash Position	$1,819,000	$176,000	$47,000	$510,000
Changes In Cash	$10,161,000	$1,643,000	$129,000	$-463,000
Proceeds From Stock Option Exercised	$7,701,000	$4,619,000	$772,000	$-4,940,000
Net Issuance Payments Of Debt	$-67,000	$-4,410,000	$3,530,000	$3,481,000
Net Long Term Debt Issuance	$-67,000	$-4,410,000	$3,530,000	$3,481,000
Long Term Debt Payments	$-834,000	$-6,102,000	$-5,270,000	$-78,000
Long Term Debt Issuance	$767,000	$1,692,000	$8,800,000	$3,559,000
Change In Working Capital	$-2,357,000	$992,000	$2,877,000	$2,552,000
Change In Other Current Liabilities	$0	$-100,000	$0	-
Change In Other Current Assets	$314,000	$313,000	$0	-
Change In Payables And Accrued Expense	$-3,018,000	$594,000	$2,962,000	$3,621,000
Change In Accrued Expense	$-920,000	$1,875,000	$517,000	$2,073,000
Change In Payable	$-2,098,000	$-1,281,000	$2,445,000	$1,548,000
Change In Account Payable	$-2,098,000	$-1,281,000	$2,445,000	$1,548,000
Change In Prepaid Assets	$538,000	$297,000	$-97,000	$-1,073,000
Change In Inventory	$-66,000	$0	-	$0
Change In Receivables	$-125,000	$-112,000	$12,000	$4,000
Changes In Account Receivables	$-125,000	$-112,000	$0	-
Other Non Cash Items	$316,000	$102,000	$48,000	$583,000
Stock Based Compensation	$624,000	$887,000	$1,930,000	$1,311,000
Unrealized Gain Loss On Investment Securities	$0	$6,145,000	$5,380,000	$0
Gain Loss On Investment Securities	$-32,000	$697,000	$763,000	$-50,000
Net Income From Continuing Operations	$-12,150,000	$-24,830,000	$-26,232,000	$-12,190,000
Gain Loss On Sale Of PPE	-	-	-	-

Fetched: 2026-06-22